Refine by
Bladder Tumor Articles & Analysis: Older
29 news found
This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development and progression. P53 is a potent tumor suppressor encoded by the TP53 gene on human chromosome 17. As a transcription factor, P53 coordinates the expression of target genes to promote cell cycle arrest, apoptosis, and DNA ...
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product ...
“We are humbled by the work in front of us in partnership with Roche as we explore the anti-tumor activity of our immunotherapy candidate in combination with atezolizumab to see if our exciting results in 1st line maintenance therapy can be extended to advanced stage disease by the use of this combination of ...
In this moderated poster presentation, the frequency of fibroblast growth factor receptor (FGFR) alterations in high-risk non-muscle invasive bladder cancer (HR-NMIBC) and the association with bacillus Calmette-Guérin (BCG) outcome will be discussed. ...
MTAP deletion is one of the most common gene deletions seen in cancers including lung, bladder, and pancreatic cancer, and is associated with poor prognosis. ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a presentation on Axumin® (fluciclovine F 18) at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in Orlando, Fla., from December 1 to 3, 2021. The Society of Urologic Oncology sponsors this highly ...
At first follow-up ureteroscopy, four patients had a complete response, four patients had a partial response, one of whom (with a history of low-grade bladder cancer) also had a bladder tumor. Four of the seven patients who have had more than one surveillance ureteroscopy had an initial complete response. ...
The primary endpoint of the study is safety and secondary endpoints are progression-free survival as well as other measures of anti-tumor activity and immunologic response. The trial is funded by a grant awarded to Mayo Clinic in Minnesota (awardee) and to Treos (sub-awardee) by the U.S. ...
” About LG IR NMIBC Out of the 80,000 estimated cases of bladder cancer per year in the U.S., approximately 35,000 are low-grade NMIBC patients comprised of both low-risk (approximately 15,000) and intermediate risk (approximately 20,000). ...
UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. ...
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Kasraeian Urology, a Division of Florida Physician Specialists (“Kasraeian Urology”). FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and ...
The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder. About LG-IR-NMIBC With 80,000 estimated cases of bladder cancer per year, approximately 35,000 are low-grade NMIBC patients comprised of both low-risk (approximately ...
Pacific Edge is pleased to announce today that it has reached its first commercial agreement of scale in Australia with Northern Health, a major provider of healthcare and hospital services to Melbourne’s rapidly growing outer northern suburbs. Northern Health provides healthcare services to the rapidly growing suburbs in Melbourne’s outer north through four campuses across the ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
NEW YORK and SAN JUAN, Puerto Rico, Sept. 1, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day". This urgent awareness team effort occurs while the ...
We believe our product candidate, designed with 12 computationally selected HLA Class I and II epitopes most frequently presented in mCRC tumors, has the potential to demonstrate improved anti-tumor activity for this growing patient ...
“This is the first published evidence for using an alternating schedule of a urine marker, such as Bladder EpiCheck, and cystoscopy or cytology. Due to Bladder EpiCheck’s high sensitivity for high-grade disease and high specificity, and a well-planned infrastructure, all high-grade tumors, including muscle invasive ...
” About Bladder EpiCheck® Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors. ...
The trial demonstrated that the therapy was safe and well-tolerated and induced T cell responses against multiple tumor targets. Robust immune responses by patients correlated to clinical benefits. ...